Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
M L VarterasianA M Al-Katib

Abstract

To define, in a phase I study in relapsed non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), the maximum-tolerated dose (MTD), major toxicities, and possible antitumor activity of bryostatin 1, a macrocyclic lactone. Bryostatin 1 was delivered by 72-hour continuous infusion every 2 weeks to patients with relapsed NHL or CLL, at doses that ranged from 12 microg/m2 to 180 microg/m2 per course. Correlative investigations included evaluations of total protein kinase C (PKC) in peripheral blood and lymphoid differentiation in patient tumor tissue. Twenty-nine patients were treated, including three patients with CLL and 26 with NHL. Generalized myalgia was the dose-limiting toxicity (DLT) and occurred in two of three patients treated with bryostatin 1 at 180 microg/m2 per course. Myalgias were dose-related and cumulative, and often started in the thighs and calves, improved with activity, were somewhat responsive to analgesics, and often took weeks to resolve once taken off study. Six patients were treated at the MTD of 120 microg/m2 per course. Myalgia, headache, and fatigue were common. Hematologic toxicity was uncommon. Total cumulative doses of bryostatin 1 up to 1,134 microg/m2 have been administered without un...Continue Reading

Citations

Apr 11, 2001·Current Oncology Reports·B D Cheson
Oct 10, 2007·Expert Opinion on Investigational Drugs·Klaus PodarKenneth C Anderson
Apr 13, 2011·PloS One·Michael KovochichJerome A Zack
May 3, 2001·Melanoma Research·A Y BedikianT Smith
Apr 3, 1999·British Journal of Cancer·S F ThijsenG J Ossenkoppele
Jan 5, 2001·Expert Opinion on Investigational Drugs·P A Philip, J A Zonder
Jun 10, 2008·Expert Opinion on Emerging Drugs·Shireen Kassam, Silvia Montoto
Jul 5, 2005·Expert Opinion on Investigational Drugs·H T Zhang, A L Harris
Apr 1, 2010·Chemistry, an Asian Journal·Karl J Hale, Soraya Manaviazar
Oct 2, 2003·British Journal of Cancer·A R ClampUNKNOWN Cancer Research UK Phase I/II Committee
Jan 23, 2004·Cancer Investigation·Jeremy Kortmansky, Gary K Schwartz
Apr 9, 2004·Proceedings of the National Academy of Sciences of the United States of America·Wen-Chien ChouChi V Dang
May 28, 2005·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Christine P HansJames O Armitage
Jul 5, 2001·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·A E FrankelJ G Jurcic
Dec 6, 2001·Current Oncology Reports·Helen C Swannie, Stanley B Kaye
May 5, 2009·The Oncologist·Angelo DelmonteCristiana Sessa
Jan 5, 2001·Expert Opinion on Investigational Drugs·S M KornblauM Andreeff
Aug 21, 2002·Anti-cancer Drugs·A Clamp, G C Jayson
Jan 5, 2002·Expert Opinion on Investigational Drugs·G K DyA A Adjei
Mar 25, 2000·Drugs & Aging·N Kalil, B D Cheson
Jun 19, 2010·International Journal of Hematology·Sophie Dupire, Bertrand Coiffier
Oct 22, 2002·The Journal of Pharmacology and Experimental Therapeutics·Christopher S StevensonLisa A Marshall
Jun 20, 2015·Journal of Immunology Research·Rouba Hage-SleimanGhassan Dbaibo
Apr 22, 2020·Nature Communications·Clayton HardmanPaul A Wender
Oct 17, 2003·British Journal of Cancer·S MadhusudanA L Harris
Dec 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gary K Schwartz, Manish A Shah
Jan 6, 2001·Anti-cancer Drugs·B NuijenJ H Beijnen
Jul 23, 2015·Scientific Reports·Laura DíazMa Ángeles Muñoz-Fernández
Feb 28, 2008·Journal of Natural Products·Sanjeev BanerjeeRamzi M Mohammad
Oct 2, 2001·Pharmacology & Therapeutics·M LeszczynieckaP B Fisher
Jul 29, 1999·Biochemical Pharmacology·D J Watters, P G Parsons
Jun 2, 2005·Critical Reviews in Oncology/hematology·Katsuyuki Hotta, Hiroshi Ueoka
Mar 20, 2013·Chemical Reviews·Adriana LorenteMercedes Álvarez

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Ranjana AdvaniJonathan G Drachman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
S M O'BrienKanti R Rai
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
S M O'BrienM J Keating
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
M L RothenbergG I Rodriguez
© 2021 Meta ULC. All rights reserved